Donald Trump's response to a White House attendee collapsing at a weight loss drug event sparks anger.

An announcement in the Oval Office about reducing the cost of weight-loss medications was briefly interrupted when a man collapsed near President Donald Trump. The incident occurred during a White House event with Eli Lilly and Novo Nordisk to unveil a deal for GLP-1 drugs like Wegovy and Ozempic. The man who fainted was quickly attended to by the White House Medical Unit, and the briefing resumed later that day.

The collapse happened while Eli Lilly's CEO was discussing a weight-loss initiative. Security cleared the room briefly, and the livestream was cut. The man who fainted was confirmed to be okay by the White House press secretary. Dr. Oz and Health Secretary Robert F. Kennedy Jr. were also present and involved in the response.

The administration's policy announcement aimed to lower prescription costs for GLP-1 drugs. The event resumed after the interruption, with details of Medicare coverage and pricing reductions outlined. The White House emphasized commitments to align U.S. prices with other countries.

Questions arose about the man's identity, with speculation that he was a Novo Nordisk executive debunked by the company. The focus shifted back to the pricing measures proposed by the administration, including promises of reduced out-of-pocket costs and special pricing for new formulations.

The incident prompted a debate on social media about Trump's reaction and leadership style during emergencies. Despite the interruption, the policy measures remained the central topic. The day concluded with the man stabilized and the policy changes still in focus for patients and payers.